Twitter Watch [accessed 31 March 2012 - 16:55]

Twitter Watch [accessed 31 March 2012 - 16:55]
Items of interest from a variety of twitter feeds associated with immunization, vaccines and global public health. This capture is highly selective and is by no means intended to be exhaustive.

GAVI Alliance ‏ @GAVIAlliance
“Preventing #measles will help #Myanmar reduce under 5 deaths & achieve #MDG4.” Pe Thet Khi, Myanmar Health Minister http://ht.ly/9ZGfw
4:38 AM – 31 Mar 12

PATH ‏ @PATHtweets
A plastic liner developed by PATH helps keep #vaccine coolers the right temperature. How does that work? http://ow.ly/9YZ16
12:47 PM – 30 Mar 12

Amanda Glassman ‏ @glassmanamanda
Linking Investments to Outcomes: Measuring Health System Effectiveness : come to our event http://www.cgdev.org/content/calendar/detail/1426059/ via @CGDev
3:15 PM – 29 Mar 12

CDCgov ‏ @CDCgov
Measles continues to be brought into U.S. Stay current on vaccines, including before travel abroad. http://go.usa.gov/Ee3
10:00 AM – 29 Mar 12

The Global Fund ‏ @globalfundnews
Our Corp Champion @Chevron talks about the key role of the private sector in the fight against #AIDS #TB & #malaria http://bit.ly/HiKPry
9:00 AM – 28 Mar 12

Amanda Glassman ‏ @glassmanamanda
MDGs should linked to human rights – “ensuring entitlements that link human rights provisions with laws and resources” http://bit.ly/HgAAnI
11:36 PM – 27 Mar 12

UNOCHA ‏ @UNOCHA
Providing life-saving measles immunizations in #Yemen: http://bit.ly/HhWlTg @UNCERF gives $5 million to support @UNICEF & @WHO response.
Retweeted by UNICEF

EndPolioNow ‏ @EndPolioNow
Rotarians in Côte d’Ivoire take part in polio immunizations as part of a coordinated 22 African country campaign. http://twitpic.com/9268qq
6:34 PM – 27 Mar 12

Sabin Vaccine Inst. ‏ @sabinvaccine
Via @nprnews: In Haiti, Bureaucratic Delays Stall Mass Cholera Vaccinations http://n.pr/GRaUwj
10:20 AM – 27 Mar 12

IVI: An Investment Case for the Accelerated Introduction of Oral Cholera Vaccines

Report: An Investment Case for the Accelerated Introduction of Oral Cholera Vaccines
IVI (International Vaccines Institute); March 2012

IVI said its Policy & Economic Research Unit has developed an investment case in order to provide a global evidence base for investing in oral cholera vaccines (as part of a larger strategy that includes improvements to water, sanitation, and hygiene). This report was developed in response “to the fact that demand for oral cholera vaccines has been too uncertain for vaccine producers to invest in increasing their production capacity beyond current low levels. This has led to reluctance among suppliers, inadequate supply, and high prices that have delayed the introduction of new and under-utilized vaccines in developing countries where cholera remains a persistent public health problem.”

IVI said the report was developed “to meet the needs of groups that include the WHO Strategic Advisory Group of Experts on Immunization (SAGE), the global health community, vaccine manufacturers, prospective donor agencies, and policymakers from cholera-endemic countries for more information about the potential demand for cholera vaccines, the cost involved to meet this demand, and the impact and cost-effectiveness of vaccination.”  The report provides further evidence to support the WHO’s recommendations (WHO Position Paper on Cholera Vaccines, March 2010) that include prioritizing cholera control measures such as immunization and water and sanitation improvements in endemic areas, consideration of preemptive vaccination in preventing outbreaks, and targeting high-risk areas and groups for vaccination in endemic countries.

Specifically the report provides:
– A detailed estimate of the cholera disease burden;
– The forecast of cholera vaccine demand for the control of endemic cholera;
– An estimate of the needs for a vaccine stockpile that could be used for pre-emptive vaccination to prevent outbreaks;
– An analysis of the global impact of vaccination on the disease based on the demand forecast results; and
– The cost and cost-effectiveness of vaccination

Financial support was provided by the Bill & Melinda Gates Foundation, the Swedish International Development Cooperation Agency (Sida), and the governments of the Republic of Korea, Sweden, and Kuwait.

http://www.ivi.int/publication/IVI_Global_cholera_case.pdf

GHSi: Shifting Paradigms – How the BRICS Are Reshaping Global Health and Development

Report: Shifting Paradigms: How the BRICS Are Reshaping Global Health and Development
Global Health Strategies initiatives (GHSi); March 2012
http://www.ghsinitiatives.org/brics-report

Executive Summary Extract
“…This report presents findings from a qualitative and quantitative survey of present and future efforts by Brazil, Russia, India, China and South Africa to improve global health. It examines these roles within the broader context of international development and foreign assistance, though health remains the primary focus. This report also includes a brief look at other emerging powers beyond the BRICS that have potential to

impact major global health issues. The goal was to examine existing BRICS assistance programs and contributions to health innovation in order to identify opportunities for the BRICS and other emerging powers to expand upon their achievements and increase their contributions to improving health in the poorest countries.”

BRICS Report
BRICS Timeline
Executive Summary
Press Release

BVGH: Developing New Drugs and Vaccines for Neglected Diseases of the Poor – The Product Developer Landscape

Report: Developing New Drugs and Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape

BIO Ventures for Global Health (BVGH); March 2012

“…Understanding the neglected disease R&D pipeline as well as the spectrum of organizations participating in the development of these new drugs and vaccines is essential to evaluating the efficiency and effectiveness of current R&D programs — and to inform the design of new ones. Until now, this type of analysis has been hindered in part because neglected disease pipelines have not been systematically tracked or analyzed. Recognizing this…BVGH collected and reviewed data from our Global Health Primer to — for the first time — shed light on the different types of organizations that are participating in product development for a broad range of neglected diseases…academic and research institutions participate in 43% of all neglected disease products in development. That participation is broad and deep but often under recognized. Product development partnerships, or PDPs, support approximately 40% of the overall neglected disease pipeline. Industry participation in product development is similar for products with and without PDP development partners. We note in the report that these findings are quantitative and do not reflect the scope and depth of the valuable work produced by these organizations through the R&D work they have undertaken…”

IOM: Crisis Standards of Care – A Systems Framework for Catastrophic Disaster Response

Report: Crisis Standards of Care: A Systems Framework for Catastrophic Disaster Response
IOM; March 21, 2012

At the request of the HHS, the IOM formed a committee in 2009, which developed guidance that health officials could use to establish and implement standards of care during disasters. In its first report, the committee defined “crisis standards of care” (CSC) as a state of being that indicates a substantial change in health care operations and the level of care that can be delivered in a public health emergency, justified by specific circumstances. During disasters, medical care must promote the use of limited resources to benefit the population as a whole. In this report, the IOM examines the effect of its 2009 report, and develops vital templates to guide the efforts of professionals and organizations responsible for CSC planning and implementations. http://www.iom.edu/Reports/2012/Crisis-Standards-of-Care-A-Systems-Framework-for-Catastrophic-Disaster-Response.aspx

[Editor’s Note: The report includes case examples involving the H1N1 pandemic and vaccine availability in its analysis]

Bulletin of the World Health Organization: Special theme – influenza

Bulletin of the World Health Organization
Volume 90, Number 4, April 2012, 245-320

http://www.who.int/bulletin/volumes/90/4/en/index.html

Special theme: influenza
In this special theme issue, Michael L Perdue & Tim Nguyen (246) look at the WHO public health research agenda for influenza two years from its initial publication. Nahoko Shindo & Sylvie Briand (247) discuss influenza at the beginning of the 21st century, while, in an interview, William Ampofo (254–255) tells Ben Jones why it is essential to track the burden of influenza in Africa.